ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.70
+0.04 (+6.06%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.66
Open0.68
Bid0.69 x 0
Ask0.71 x 0
Day's Range0.67 - 0.71
52 Week Range0.19 - 1.13
Volume293,363
Avg. Volume239,673
Market Cap98.491M
Beta2.40
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.86
  • Zacks Small Cap Research8 days ago

    Oncolytics’ (ONCYF) Signs $87 Million Deal with Adlai Nortye

    By John Vandermosten, CFA OTC:ONCYF TSX:ONC.TO Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a licensing deal with Adlai Nortye (NEEQ: 870946) to provide upfront licensing and milestones of $21.2 ...

  • CNW Group8 days ago

    Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

    Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

  • PR Newswire8 days ago

    Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

    CALGARY and SAN DIEGO, CA, Nov. 16, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced that it has entered into a Regional Licensing Agreement (The Agreement) with Adlai Nortye (Adlai), a biopharmaceutical company focused on discovering and developing important new treatments for cancer and metabolic diseases. Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.

  • ACCESSWIRE16 days ago

    Today’s Research Reports on Cardiome Pharma, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Oncolytics Biotech Inc.

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE17 days ago

    Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

    LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...

  • Associated Press17 days ago

    Oncolytics reports 3Q loss

    The Calgary, Alberta-based company said it had a loss of 2 cents per share. The company's shares closed at 44 cents. A year ago, they were trading at 18 cents. _____ This story was generated by Automated ...

  • CNW Group17 days ago

    Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

    Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

  • PR Newswire17 days ago

    Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

    CALGARY , and SAN DIEGO, CA , Nov. 8, 2017 /PRNewswire/ - Oncolytics Biotech ® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN ® , an intravenously delivered ...

  • PR Newswire23 days ago

    Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

    CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced the appointment of Deborah M. Brown, B.Sc., M.B.A., to Oncolytics' Board of Directors. "Ms. Brown's wealth of experience in new product launches and market expansion will lend valuable insights as we progress REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. In addition to being a Management Consultant since 2014, Ms. Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies.

  • CNW Group23 days ago

    Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

    Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

  • PR Newswirelast month

    Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

    CALGARY and SAN DIEGO, Oct. 11, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF), a biotech company developing REOLYSIN®, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that Matt Coffey, Ph.D., President & Chief Executive Officer, will present a corporate overview and outline strategic objectives at the 2017 BIO Investor Forum.

  • CNW Grouplast month

    Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

    Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

  • ACCESSWIRE2 months ago

    Research Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

    LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...

  • Zacks Small Cap Research2 months ago

    Oncolytics’ (ONCYF) End of Phase II Meeting

    By John Vandermosten, CFA OTC:ONCYF TSX:ONC.V Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a successful end of Phase II meeting with the FDA in a September 18 press release.  The purpose of the ...

  • PR Newswire2 months ago

    Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

    CALGARY and SAN DIEGO, Sept. 19, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that it will present at the Phacilitate Immuno-Oncology Frontiers Conference.  Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and 21st in Berlin, Germany.

  • CNW Group2 months ago

    Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

    Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

  • PR Newswire2 months ago

    Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

    CALGARY and SAN DIEGO, Sept. 18, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep) a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S.

  • CNW Group2 months ago

    Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

    Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

  • PR Newswire2 months ago

    Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

    CALGARY and SAN DIEGO, Sept. 14, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep), a first-in-class, systemically delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients. "This is an important trial for Oncolytics as it's the first to discretely examine the innate immunity component of REOLYSIN's mechanism of action," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

  • CNW Group2 months ago

    Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

    Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

  • CNW Group2 months ago

    Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

    Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

  • PR Newswire2 months ago

    Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

    Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients Largest immuno-oncolytic virus safety database ...

  • ACCESSWIRE3 months ago

    Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

    LONDON, UK / ACCESSWIRE / September 5, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...

  • Zacks Small Cap Research3 months ago

    Oncolytics’ (ONCYF) Second Quarter Results

    Oncolytics Biotech, Incorporated’s (ONCYF) second quarter began with a rush of activity as the company presented compelling data from its IND 213 study at AACR followed by an announcement of fast track designation by the FDA and presentation at ASCO in May.  The strong data from the metastatic breast cancer trial indicated a 17 month benefit from REOLYSIN (compared to 10 months for chemotherapy alone) and opens the opportunity for breakthrough designation which could be announced in October.  In preparation for a Phase III trial, Oncolytics raised additional capital in May which is expected to fund operations until late next year. The second half of 2017 will emphasize the interactions with the FDA and how this will impact the design of the Phase III trial for metastatic breast cancer.  There is also the possibility to receive breakthrough designation which will expedite the FDA’s review of REOLYSIN.  Potential collaborators are watching this process closely and we anticipate that there will be more to announce regarding a partner for the Phase III trial before the end of the year.

  • Associated Press4 months ago

    Oncolytics reports 2Q loss

    On a per-share basis, the Calgary, Alberta-based company said it had a loss of 2 cents. The company's shares closed at 40 cents. A year ago, they were trading at 32 cents. _____ This story was generated ...